Nuvalent reports $658M cash, FDA breakthrough therapy for two candidates, net loss $57.2M in Q2

Nuvalent, Inc.

2024-Q2 EPS reported -$1.58

Cash, equivalents and securities $658.0M as of June 30, 2024; operating runway into 2027.
Net loss $57.2M for Q2 2024; R&D expense $49.2M, G&A $16.0M.
FDA breakthrough therapy designation for zidesamtinib (ROS1) and NVL-655 (ALK).
Phase 2 enrollment ongoing for ALKOVE-1 (NVL-655) and ARROS-1 (zidesamtinib) with registrational intent; ESMO updates September 14.
Initiated HEROEX-1 Phase 1a/1b trial for NVL-330 in HER2-altered NSCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.